Objective:Functional dyspepsia(FD)is a widely prevalent gastrointestinal disorder throughout the world,whereas the efficacy of current treatment in the Western countries is limited.The traditional Chinese herbal formu...Objective:Functional dyspepsia(FD)is a widely prevalent gastrointestinal disorder throughout the world,whereas the efficacy of current treatment in the Western countries is limited.The traditional Chinese herbal formula Xiaopi Hewei capsule(XHC)is a clinically validated remedy in treating FD,but there is no literature expounds the underlying therapeutic mechanism of XHC so far.Methods:In the present study,the network pharmacology technology was used to explore the therapeutic mechanism of XHC in treating FD.We obtained relative compounds of XHC,potential targets of these compounds and FD-related targets by retrieving particular websites.Based on the matching results between XHC potential targets and disease targets,Protein-Protein Interaction(PPI)network was constructed to screen the hub targets by topology.Furthermore,DAVID bioinformatics resources were utilized for the enrichment analysis on GO and KEGG.Results:A total of 62 active compounds and 547 putative identified targets were screened from XHC,of which 241 overlapped with the targets of FD and were considered potential therapeutic targets.14 hub genes were recognized as potential targets of treatments.Moreover,the results of DAVID enrichment analysis indicated that XHC participated in the complex treating effects associated with anti-depression,inflammatory reaction and eradicating Helicobacter Pylori(HP).Molecular docking stimulation results showed that most bioactive compounds of XHC had a strong binding efficiency with hub genes.Conclusions:This study demonstrated that XHC has the characteristics of multi-compounds,multi-targets and multi-pathways in treating FD,which provides the theoretical basis for further research of XHC.展开更多
Objective： To observe the therapeutic efficacy of Xiaopi-Ⅰ （消痞Ⅰ号） on functional dyspepsia and its effects on gastric emptying. Methods： A total of 134 patients with functional dyspepsia were randomly assigned...Objective： To observe the therapeutic efficacy of Xiaopi-Ⅰ （消痞Ⅰ号） on functional dyspepsia and its effects on gastric emptying. Methods： A total of 134 patients with functional dyspepsia were randomly assigned to 2 groups. The patients in the Xiaopi-Ⅰ group （66 cases） and the Domperidone group （68 cases） were given Xiaopi- Ⅰ granules and Domperidone 10 mg, 3 times a day, respectively. Another 20 healthy volunteers were chosen as the negative control group. The severity scores of the symptoms, as well as the gastric emptying, were detected before and after 4-week treatment by barium strip-trial meal. Results： During therapy, 6 cases from the Xiaopi- Ⅰ group and 8 cases from the Domperidone group were lost to follow, and 120 cases finally finished the study. Statistical differences were observed from both groups in terms of the symptoms of postprandial fullness early satiety, epigastric pain, and epigastric burning after 4-week treatment （P〈0.01）. The symptomatic severity scores of the Xiaopi- Ⅰ group before and after the treatment were 7.48±1.64 and 2.16 ± 1.26, respectively （P〈0.01）. Gastric emptying rates were also improved in the patients with delayed gastric emptying, and the effective rates were 91.3% and 75.8% in the Xiaopi- Ⅰ and Domperidone groups, respectively. No obvious adverse effects were found from both groups. Conclusion： Xiaopi- Ⅰ was an effective and safe agent in the treatment of functional dyspepsia and was worth of further development in clinical.展开更多
基金This work was financial supported by the Major science and technology projects in Tibet region(Grant No:XZ201801-GA-16)School-enterprise cooperation project(Grant No:2019110031001686).
文摘Objective:Functional dyspepsia(FD)is a widely prevalent gastrointestinal disorder throughout the world,whereas the efficacy of current treatment in the Western countries is limited.The traditional Chinese herbal formula Xiaopi Hewei capsule(XHC)is a clinically validated remedy in treating FD,but there is no literature expounds the underlying therapeutic mechanism of XHC so far.Methods:In the present study,the network pharmacology technology was used to explore the therapeutic mechanism of XHC in treating FD.We obtained relative compounds of XHC,potential targets of these compounds and FD-related targets by retrieving particular websites.Based on the matching results between XHC potential targets and disease targets,Protein-Protein Interaction(PPI)network was constructed to screen the hub targets by topology.Furthermore,DAVID bioinformatics resources were utilized for the enrichment analysis on GO and KEGG.Results:A total of 62 active compounds and 547 putative identified targets were screened from XHC,of which 241 overlapped with the targets of FD and were considered potential therapeutic targets.14 hub genes were recognized as potential targets of treatments.Moreover,the results of DAVID enrichment analysis indicated that XHC participated in the complex treating effects associated with anti-depression,inflammatory reaction and eradicating Helicobacter Pylori(HP).Molecular docking stimulation results showed that most bioactive compounds of XHC had a strong binding efficiency with hub genes.Conclusions:This study demonstrated that XHC has the characteristics of multi-compounds,multi-targets and multi-pathways in treating FD,which provides the theoretical basis for further research of XHC.
文摘Objective： To observe the therapeutic efficacy of Xiaopi-Ⅰ （消痞Ⅰ号） on functional dyspepsia and its effects on gastric emptying. Methods： A total of 134 patients with functional dyspepsia were randomly assigned to 2 groups. The patients in the Xiaopi-Ⅰ group （66 cases） and the Domperidone group （68 cases） were given Xiaopi- Ⅰ granules and Domperidone 10 mg, 3 times a day, respectively. Another 20 healthy volunteers were chosen as the negative control group. The severity scores of the symptoms, as well as the gastric emptying, were detected before and after 4-week treatment by barium strip-trial meal. Results： During therapy, 6 cases from the Xiaopi- Ⅰ group and 8 cases from the Domperidone group were lost to follow, and 120 cases finally finished the study. Statistical differences were observed from both groups in terms of the symptoms of postprandial fullness early satiety, epigastric pain, and epigastric burning after 4-week treatment （P〈0.01）. The symptomatic severity scores of the Xiaopi- Ⅰ group before and after the treatment were 7.48±1.64 and 2.16 ± 1.26, respectively （P〈0.01）. Gastric emptying rates were also improved in the patients with delayed gastric emptying, and the effective rates were 91.3% and 75.8% in the Xiaopi- Ⅰ and Domperidone groups, respectively. No obvious adverse effects were found from both groups. Conclusion： Xiaopi- Ⅰ was an effective and safe agent in the treatment of functional dyspepsia and was worth of further development in clinical.
